US 12,312,400 B2
Engineered anti-il-2 antibodies
Inbar Amit, Modiin (IL); Itay Levin, Herzeliya (IL); Guy Nimrod, Tel Aviv (IL); Sharon Fischman, Modi'in (IL); Reut Barak Fuchs, Rehovot (IL); Marek Strajbl, Jerusalem (IL); Timothy Wyant, Bellingham, MA (US); Michael Zhenin, Jerusalem (IL); Olga Bluvshtein Yermolaev, Rishon-LeZion (IL); Yehezkel Sasson, Tzur Yigal (IL); Noam Grossman, Mazkeret Batyia (IL); Natalia Levitin, Ashdod (IL); and Yanay Ofran, Tel Aviv (IL)
Assigned to AULOS BIOSCIENCE, INC., Larkspur, CA (US)
Appl. No. 17/795,960
Filed by Aulos Bioscience, Inc, Larkspur, CA (US)
PCT Filed Feb. 15, 2021, PCT No. PCT/IB2021/051267
§ 371(c)(1), (2) Date Jul. 28, 2022,
PCT Pub. No. WO2021/161287, PCT Pub. Date Aug. 19, 2021.
Claims priority of provisional application 63/139,315, filed on Jul. 28, 2022.
Claims priority of provisional application 62/977,292, filed on Jul. 28, 2022.
Prior Publication US 2023/0085471 A1, Mar. 16, 2023
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/246 (2013.01) [A61K 39/395 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 28 Claims
 
1. An isolated anti-IL-2 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, and said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein
(a) the HCDR1 comprises amino acids 26-33 of SEQ ID NO: 10, the HCDR2 comprises amino acids 51-58 of SEQ ID NO: 10, the HCDR3 comprises amino acids 97-110 of SEQ ID NO: 10, the LCDR1 comprises amino acids 27-38 of SEQ ID NO: 11, the LCDR2 comprises the amino acids 56-58 of SEQ ID NO: 11, and the LCDR3 comprises the amino acids 95-103 of SEQ ID NO: 11;
(b) the HCDR1 comprises amino acids 26-33 of SEQ ID NO: 12, the HCDR2 comprises amino acids 51-58 of SEQ ID NO: 12, the HCDR3 comprises amino acids 97-110 of SEQ ID NO: 12, the LCDR1 comprises amino acids 27-38 of SEQ ID NO: 13, the LCDR2 comprises the amino acids 56-58 of SEQ ID NO: 13, and the LCDR3 comprises the amino acids 95-103 of SEQ ID NO: 13;
(c) the HCDR1 comprises amino acids 26-33 of SEQ ID NO: 14, the HCDR2 comprises amino acids 51-58 of SEQ ID NO: 14, the HCDR3 comprises amino acids 97-110 of SEQ ID NO: 14, the LCDR1 comprises amino acids 27-38 of SEQ ID NO: 15, the LCDR2 comprises the amino acids 56-68 of SEQ ID NO: 15, and the LCDR1 comprises the amino acids 95-103 of SEQ ID NO: 15;
(d) the HCDR1 comprises amino acids 26-33 of SEQ ID NO: 16, the HCDR2 comprises amino acids 51-58 of SEQ ID NO: 16, the HCDR3 comprises amino acids 97-110 of SEQ ID NO: 16, the LCDR1 comprises amino acids 27-38 of SEQ ID NO: 17, the LCDR2 comprises the amino acids 56-58 of SEQ ID NO: 17, and the LCDR3 comprises the amino acids 95-103 of SEQ ID NO: 17; or
(e) the HCDR1 comprises amino acids 26-33 of SEQ ID NO: 18, the HCDR2 comprises amino acids 51-58 of SEQ ID NO: 18, the HCDR3 comprises amino acids 97-110 of SEQ ID NO: 18, the LCDR1 comprises amino acids 27-38 of SEQ ID NO: 19, the LCDR2 comprises the amino acids 56-58 of SEQ ID NO: 19, and the LCDR3 comprises the amino acids 95-103 of SEQ ID NO: 19.